ABSTRACT
Introduction Synthetic opioids cause tens of thousands of deaths annually in North America and appear to be increasing in Europe. This study examined high-risk substance use in the German drug-using community with a particular focus on the synthetic opioids fentanyl and nitazenes.
Methods A cross-sectional online survey was conducted in the drug-using community in Germany (August–September 2025). The sample included 235 individuals aged ≥14 years (mean age=43.4 years; 57.9% male), recruited by peers in open drug-use scenes (79.6%) and in addiction clinics and opioid substitution services. The primary outcome was past 12-month substance use. Additional measures included opioid sources, forms, routes of administration, perceived changes in availability and price, risk perceptions, overdose experiences, and harm-reduction behavior.
Results 227 respondents reported substance use (mean: 6.2 substances). 73.1% (95% CI=67.0– 78.5%) had used at least one opioid in the past year. Synthetic opioids were reported across regions and all age and gender groups. Among participants reporting a shortage of their primary opioid, 25.0% (95% CI=15.8–37.2%) used fentanyl as a substitute. 56.5% (95% CI=36.8–74.3%) of synthetic opioid users reported an overdose in the past 12 months. Most respondents perceived synthetic opioids as highly risky and feared contamination, but only 9.9% (95% CI=6.6–14.7%) use drug-checking services.
Conclusions Synthetic opioids have entered the German drug scene and are associated with high overdose rates and limited access to harm-reduction measures. These findings indicate an emerging synthetic opioid transition in Germany and highlight the need for expanded surveillance, naloxone distribution, and drug-checking services.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the State Medical Association (Landesaerztekammer) Baden-Wuerttemberg gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
other structure of the abstract and update of references
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Funder Information Declared
